{"id":941109,"date":"2026-03-02T13:41:29","date_gmt":"2026-03-02T18:41:29","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-participation-in-two-upcoming-investor-conferences\/"},"modified":"2026-03-02T13:41:29","modified_gmt":"2026-03-02T18:41:29","slug":"palisade-bio-announces-participation-in-two-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-participation-in-two-upcoming-investor-conferences\/","title":{"rendered":"Palisade Bio Announces Participation in Two Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">\n        <strong>Carlsbad, CA, March  02, 2026  (GLOBE NEWSWIRE) &#8212; <\/strong>Palisade Bio, Inc. (Nasdaq: PALI) (\u201cPalisade\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that management will participate in two upcoming investor conferences taking place during March 2026. Details are as follows:<\/p>\n<p align=\"justify\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lCTef0_AGSpiB5oIwOOp7lLif3R8GFmkSZaUGXJebL9hm4ICpaWnMJAXfsRZra6bL28MP3Cvd7MA-iF1v8zoeEW4KWLMRriV3X5RnNWulRGO8rGFhPvpy_VHyC9scPadJSdW0P2sAP8kJ0UKr3go1g==\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <b>TD Cowen 46th Annual Health Care Conference<\/b><br \/>\n        <\/a><br \/>\n        <br \/>\n        <b>Date\/time: <\/b>March 2, 2026 at 3:10 PM EST<br \/><b>Location: <\/b>Boston Mariott Copley Place, Boston, MA<br \/><b>Format: <\/b>In-person presentation &amp; investor meetings<br \/><b>Webcast link: <\/b><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oI_AZlFXJnKZFGLaibkUz-lc1lGO9ywyNTwrn1ykBIq12EySueAlC6JlSGUcxFJZ1TzHUjPAiMIkeWL_RGAhi7awd2T8Yzx1jebbidWVXRB228eSMEr_Oy1CKCi5ho-7HwLuO8QRyZWcdriPe7mdCbSMEjINUamJ4hg6r-qcZ7Y=\" rel=\"nofollow\" target=\"_blank\">Register here<\/a><\/p>\n<p align=\"justify\">Investors registered to attend the conference who wish to meet with Palisade Bio management should contact the TD Cowen one-on-one desk to request a meeting.<\/p>\n<p align=\"justify\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JBMZBgNzM_x-IDtslpJMD3BREWI2oKxIhHehZ64SyuIX1h_4lmt_iGMX9ROfDGfUFf8nSvniKKl2-HRc-I2KGZXqFi-WFMfB1BDZKWKLGbyDQ57eawC5rUM9rRltFh6fM-u2o_HB_XF7GiJQvbs0ow==\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <b>Leerink Partners 2026 Global Healthcare Conference<\/b><br \/>\n        <\/a><br \/>\n        <br \/>\n        <b>Date: <\/b>March 8-11, 2026<br \/><b>Location: <\/b>W South Beach, Miami, FL<br \/><b>Format: <\/b>One-on-one investor meetings<\/p>\n<p align=\"justify\">Investors registered to attend the conference who wish to meet with Palisade Bio management should contact the Leerink one-on-one desk to request a meeting.<\/p>\n<p align=\"justify\">\n        <b>About Palisade Bio<\/b>\n      <\/p>\n<p align=\"justify\">Palisade Bio, Inc. (Nasdaq: PALI) (\u201cPalisade\u201d or the \u201cCompany\u201d) is a clinical-stage biopharmaceutical company advancing a next generation oral PDE4 inhibitor prodrugs designed to improve pharmacology, tolerability and convenience for patients with inflammatory and fibrotic diseases. Through its differentiated prodrug platform and precision pharmacology strategy, Palisade Bio is committed to transforming proven PDE4 biology into better, safer oral therapies for patients living with chronic inflammatory and fibrotic diseases.<\/p>\n<p align=\"justify\">The Company\u2019s lead program, PALI-2108, is a once-daily oral PDE4 inhibitor prodrug designed to be selectively bioactivated in the ileum and colon, initiating targeted PDE4 inhibition at sites of disease while enabling systemic distribution of the active drug. In a recently reported Phase 1b trial, PALI-2108 achieved a 100% clinical response in the UC cohort, with no serious adverse events, favorable tolerability and pharmacokinetics consistent with localized activation in the lower intestine, low systemic exposure, and controlled release within the GI tract.<\/p>\n<p align=\"justify\">Palisade Bio is now advancing towards a Phase 2 clinical study in UC designed to evaluate clinical remission, response and pharmacodynamic biomarkers over 12 weeks, with an extension phase assessing maintenance of remission. In addition, the Company is completing early studies in fibrostenotic crohn\u2019s disease to further characterize PALI-2108\u2019s safety, pharmacology and potential therapeutic benefit across inflammatory bowel disease indications. For more information, please go to <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DP9lAIqo7uITY3qw9BbCdYnkRyB36iMZVA6xNwLW0dwMK-i7qI7zpKuQmh8knuUmeNCs_7mrp9Es_vS3Mw94IDdEl4YBsSnviYqUQKCc6A4=\" rel=\"nofollow\" target=\"_blank\">www.palisadebio.com<\/a>.<\/p>\n<p align=\"justify\">\n        <b>Forward Looking Statements<\/b>\n      <\/p>\n<p align=\"justify\">Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include but are not limited to: statements regarding the timing and results of clinical trials, the potential mechanisms of action and therapeutic benefits of PALI-2108, and plans for regulatory submissions. These forward-looking statements are based on the Company\u2019s current expectations. Forward-looking statements involve risks and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the Company\u2019s forward-looking statements include, among others, the timing of enrollment, commencement and completion of the Company\u2019s clinical trials; the Company\u2019s reliance on PALI-2108, and its early stage of clinical development; the risk that prior results, such as signals of safety, clinical response, dosing or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving the Company\u2019s product candidates in clinical trials focused on the same or different indications; and other factors that are described in the \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations\u201d sections of the Company\u2019s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission (\u201cSEC\u201d) on March 24, 2025, and the Quarterly Reports on Form 10-Q or other SEC filings that are filed thereafter. Investors are cautioned not to put undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof, and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company\u2019s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.<\/p>\n<p align=\"justify\">\n        <b>Investor Relations Contact<\/b>\n      <\/p>\n<p align=\"justify\">JTC Team, LLC<br \/>Jenene Thomas<br \/>908-824-0775<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qFcyOKxvt4XS8VkvHz8D-P84p0FEzZihq1aFBbO08XqMQEgMGohjTfWHalvQuiP4TF4iQqjDyghK4q92IZrY62BMwiQk044NolIRE3mr_06Z9hreXr5YhYsgas1xg3hYZd3b3pE_GpdCRgUcb7ojB0rMFatWpGwiB8FzLzzBdSJ-9XSKmx3CF8W0mYWKSNppywSnjSUy50TBIQEdYOLSdA==\" rel=\"nofollow\" target=\"_blank\">PALI@jtcir.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2MzUzMiM3NDYxMTc3IzUwMDEwOTEyMQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/M2EyN2JhM2ItMGM1ZS00YTE4LTgzMjItODA0MmQzYTc0NTNmLTUwMDEwOTEyMS0yMDI2LTAzLTAyLWVu\/tiny\/Palisade-Bio-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Carlsbad, CA, March 02, 2026 (GLOBE NEWSWIRE) &#8212; Palisade Bio, Inc. (Nasdaq: PALI) (\u201cPalisade\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that management will participate in two upcoming investor conferences taking place during March 2026. Details are as follows: TD Cowen 46th Annual Health Care Conference Date\/time: March 2, 2026 at 3:10 PM ESTLocation: Boston Mariott Copley Place, Boston, MAFormat: In-person presentation &amp; investor meetingsWebcast link: Register here Investors registered to attend the conference who wish to meet with Palisade Bio management should contact the TD Cowen one-on-one desk to request a meeting. Leerink Partners 2026 Global Healthcare Conference Date: March &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-participation-in-two-upcoming-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Palisade Bio Announces Participation in Two Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-941109","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Palisade Bio Announces Participation in Two Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-participation-in-two-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Palisade Bio Announces Participation in Two Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Carlsbad, CA, March 02, 2026 (GLOBE NEWSWIRE) &#8212; Palisade Bio, Inc. (Nasdaq: PALI) (\u201cPalisade\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that management will participate in two upcoming investor conferences taking place during March 2026. Details are as follows: TD Cowen 46th Annual Health Care Conference Date\/time: March 2, 2026 at 3:10 PM ESTLocation: Boston Mariott Copley Place, Boston, MAFormat: In-person presentation &amp; investor meetingsWebcast link: Register here Investors registered to attend the conference who wish to meet with Palisade Bio management should contact the TD Cowen one-on-one desk to request a meeting. Leerink Partners 2026 Global Healthcare Conference Date: March &hellip; Continue reading &quot;Palisade Bio Announces Participation in Two Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-participation-in-two-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-02T18:41:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2MzUzMiM3NDYxMTc3IzUwMDEwOTEyMQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-participation-in-two-upcoming-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-participation-in-two-upcoming-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Palisade Bio Announces Participation in Two Upcoming Investor Conferences\",\"datePublished\":\"2026-03-02T18:41:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-participation-in-two-upcoming-investor-conferences\\\/\"},\"wordCount\":720,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-participation-in-two-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2MzUzMiM3NDYxMTc3IzUwMDEwOTEyMQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-participation-in-two-upcoming-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-participation-in-two-upcoming-investor-conferences\\\/\",\"name\":\"Palisade Bio Announces Participation in Two Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-participation-in-two-upcoming-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-participation-in-two-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2MzUzMiM3NDYxMTc3IzUwMDEwOTEyMQ==\",\"datePublished\":\"2026-03-02T18:41:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-participation-in-two-upcoming-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-participation-in-two-upcoming-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-participation-in-two-upcoming-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2MzUzMiM3NDYxMTc3IzUwMDEwOTEyMQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2MzUzMiM3NDYxMTc3IzUwMDEwOTEyMQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-participation-in-two-upcoming-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Palisade Bio Announces Participation in Two Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Palisade Bio Announces Participation in Two Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-participation-in-two-upcoming-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Palisade Bio Announces Participation in Two Upcoming Investor Conferences - Market Newsdesk","og_description":"Carlsbad, CA, March 02, 2026 (GLOBE NEWSWIRE) &#8212; Palisade Bio, Inc. (Nasdaq: PALI) (\u201cPalisade\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that management will participate in two upcoming investor conferences taking place during March 2026. Details are as follows: TD Cowen 46th Annual Health Care Conference Date\/time: March 2, 2026 at 3:10 PM ESTLocation: Boston Mariott Copley Place, Boston, MAFormat: In-person presentation &amp; investor meetingsWebcast link: Register here Investors registered to attend the conference who wish to meet with Palisade Bio management should contact the TD Cowen one-on-one desk to request a meeting. Leerink Partners 2026 Global Healthcare Conference Date: March &hellip; Continue reading \"Palisade Bio Announces Participation in Two Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-participation-in-two-upcoming-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-02T18:41:29+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2MzUzMiM3NDYxMTc3IzUwMDEwOTEyMQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-participation-in-two-upcoming-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-participation-in-two-upcoming-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Palisade Bio Announces Participation in Two Upcoming Investor Conferences","datePublished":"2026-03-02T18:41:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-participation-in-two-upcoming-investor-conferences\/"},"wordCount":720,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-participation-in-two-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2MzUzMiM3NDYxMTc3IzUwMDEwOTEyMQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-participation-in-two-upcoming-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-participation-in-two-upcoming-investor-conferences\/","name":"Palisade Bio Announces Participation in Two Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-participation-in-two-upcoming-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-participation-in-two-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2MzUzMiM3NDYxMTc3IzUwMDEwOTEyMQ==","datePublished":"2026-03-02T18:41:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-participation-in-two-upcoming-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-participation-in-two-upcoming-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-participation-in-two-upcoming-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2MzUzMiM3NDYxMTc3IzUwMDEwOTEyMQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2MzUzMiM3NDYxMTc3IzUwMDEwOTEyMQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-participation-in-two-upcoming-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Palisade Bio Announces Participation in Two Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/941109","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=941109"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/941109\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=941109"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=941109"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=941109"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}